PANACEABIO · Panacea Biotec Ltd · Biotechnology & Drugs
PANACEABIO · Panacea Biotec Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
45.2% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹200 Cr
Revenue YoY
PAT YoY
-43.2%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
2.9
P/S (TTM)
3.6
Sector P/E
Not available from data source
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| PANACEABIO (this stock) | Not meaningful (earnings negative over the last 12 months) | 2.9 | -1.1% | -0.9% | 0.03 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 3q
MF
Not available from data source
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 20 Aug 2026 | Nosheen Sheikh | SELL | 3,000 | ₹12.29 lakh |
| 12 Jun 2026 | Dr. Rajesh Jain | SELL | 2,00,000 | ₹0 |
| 12 Jun 2026 | Rajesh Jain (HUF) | BUY | 2,00,000 | ₹0 |
Bulk/block deals
| date | canonicalSymbol | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| 2026-06-09 | PANACEABIO | 4464492 | 9 | WEAK | BULK |
| 2026-06-05 | PANACEABIO | 733281 | 2 | WEAK | BULK |
| 2026-06-04 | PANACEABIO | 314939 | 1 | STRONG | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedPanacea Biotec Limited's annual report for FY2025-26 outlines the company's strategic focus on expanding its global vaccine manufacturing footprint, enhancing sustainability initiatives, and strengthening corporate governance. The report highlights the company's efforts to register vaccines in multiple countries, including participation in the African Vaccine Manufacturing Accelerator (AVMA) initiative. It also emphasizes the company's commitment to environmental sustainability, including emission reductions and waste management. The report details the company's board composition, governance practices, and compliance with regulatory requirements.
- Expansion of global vaccine manufacturing and participation in the AVMA initiative to support African vaccine production.
- Commitment to environmental sustainability with measurable reductions in emissions and waste management.
- Strong emphasis on corporate governance, including board composition, audit processes, and compliance with regulatory standards.
Key takeaway: Panacea Biotec is focused on expanding its global vaccine manufacturing presence, enhancing sustainability efforts, and maintaining robust corporate governance practices to support long-term growth and compliance.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceRecent (last 12 months)
The auditor highlights a material uncertainty related to the company's going concern due to significant losses and negative retained earnings, indicating doubt about the company's ability to continue as a going concern.
Regulatory Action
1 occurrenceRecent (last 12 months)
In the previous year, both Stock Exchanges imposed a fine of ₹11,800 (inclusive of GST) each for a non-compliance with Regulation 29(1)(e) of the SEBI LODR Regulations regarding dividend intimation for 2023-24. The Company paid the fine and has no outstanding amount.
Routine disclosures
Contingent Liability
2 occurrencesRecent (last 12 months)
The Company is involved in disputes, lawsuits, claims, governmental and/or regulatory inspections, inquiries, investigations, and proceedings, including patent and commercial matters that arise in the ordinary course of business. The eventual outcome of the litigations is uncertain, and the Company assesses the need to make provision or disclose contingent liability on a case-to-case basis.
Older (3+ years ago)
The Company is involved in legal proceedings and tax issues across various jurisdictions, with uncertain outcomes and complex factual and legal issues. The Company accrues liabilities when an adverse outcome is probable and the loss amount can be reasonably estimated.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company has loans from related parties, which are unsecured and payable within 12 months from the date of borrowing. The interest rate is 9% p.a., and the details are disclosed in note 41.
Older (3+ years ago)
The company had transactions with related parties including rent income from Neophar, interest expenses with Dr. Rajesh Jain, Mrs. Sunanda Jain, and Mr. Soshil Kumar Jain, legal expenses with Mrs. Sunanda Jain and MR Lex Corp LLP, short-term employee benefits with multiple family members and employees, directors' sitting fees with various directors, repayment of borrowings with Mrs. Sunanda Jain, Mr. Soshil Kumar Jain, and Dr. Rajesh Jain, and year-end balances including borrowings and interest accrued with Dr. Rajesh Jain and Mr. Soshil Kumar Jain.
Statutory dues in dispute
2 occurrencesRecent (last 12 months)
The company has statutory dues disputes pending in various forums, including the High Court of Delhi and Supreme Court of India, related to income tax, disallowance of input tax credit, rebate claims, and excess credit claimed under different acts and financial years.
Older (3+ years ago)
The company has disputes over VAT and customs duties, with amounts in dispute ranging from Financial Year 2014-15 to 2016-17, pending before various VAT authorities and CTO Authority Chennai.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
3.73% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).